Prospects for Creation of Cardioprotective and Antiarrhythmic Drugs Based on Opioid Receptor Agonists.

Abstract

It has now been demonstrated that the μ, δ1 , δ2 , and κ1 opioid receptor (OR) agonists represent the most promising group of opioids for the creation of drugs enhancing cardiac tolerance to the detrimental effects of ischemia/reperfusion (I/R). Opioids are able to prevent necrosis and apoptosis of cardiomyocytes during I/R and improve cardiac contractility in the reperfusion period. The OR agonists exert an infarct-reducing effect with prophylactic administration and prevent reperfusion-induced cardiomyocyte death when ischemic injury of heart has already occurred; that is, opioids can mimic preconditioning and postconditioning phenomena. Furthermore, opioids are also effective in preventing ischemia-induced arrhythmias.

• Authors: Leonid N Maslov, Igor Khaliulin, Peter R Oeltgen, Natalia V Naryzhnaya, Jian-Ming Pei, Stephen A Brown, Yury B Lishmanov, James M Downey
• Journal: Medicinal research reviews (Med Res Rev) Vol. 36 Issue 5 Pg. 871-923 (09 2016) ISSN: 1098-1128 [Electronic] United States
• PMID: 27197922 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: © 2016 Wiley Periodicals, Inc.

Chemical References

• Analgesics, Opioid
• Anti-Arrhythmia Agents
• Cardiotonic Agents
• Receptors, Opioid

Topics

• Analgesics, Opioid (chemistry, pharmacology)
• Animals
• Anti-Arrhythmia Agents (chemistry, pharmacology)
• Cardiotonic Agents (chemistry, pharmacology)
• Drug Discovery
• Humans
• Receptors, Opioid (agonists)